



# Biotech Daily

Wednesday January 19, 2022

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECH DOWN: PHARMAXIS, USCOM UP 5%; KAZIA DOWN 7%**
- \* **GENETIC TECHNOLOGIES H1 RECEIPTS UP TO \$2.7m FROM \$15k**
- \* **ALLEGRA REVENUE, LOSS WARNING**
- \* **ADHERIUM RECEIVES \$1.6m FEDERAL R&D TAX INCENTIVE**
- \* **CYNATA RECEIVES \$833k FEDERAL R&D TAX INCENTIVE**
- \* **PETERS BUYS ANDREW GOODALL \$1.4m MEMPHASYS NOTE**
- \* **CARDIEX 10-to-1 CONSOLIDATION FOR US OTCQX LISTING**
- \* **WILLIAM BLAIR, BIONOMICS CHAIR DR DE SOUZA, LIZ DOOLIN TAKE 22%**
- \* **CEO DR PETER MEINTJES STARTS AT PACIFIC EDGE**

## MARKET REPORT

The Australian stock market fell 1.03 percent on Wednesday January 19, 2022, with the ASX200 down 76.3 points to 7,332.5 points. Seven of the Biotech Daily Top 40 stocks were up, 29 fell and four traded unchanged. All three Big Caps were down.

Pharmaxis and Uscom were the equal best, both up 0.5 cents or 4.8 percent to 11 cents, with 175,885 shares and 2,232 shares traded, respectively.

Antisense and Micro-X climbed two percent or more; Oncosil was up 1.2 percent; with Cyclopharm and Neuren up by less than one percent.

Kazia led the falls, down 7.5 cents or 6.4 percent to \$1.09, with 173,484 shares traded.

Nova Eye and Paradigm lost more than six percent; Cynata, Genetic Signatures, Imugene, Next Science and Telix fell more than five percent; Avita, Polynovo and Resmed shed more than four percent; Actinogen, Atomo, Dimerix, Medical Developments, Pro Medicus and Volpara were down more than three percent; Amplia, Cochlear, Emvision, Impedimed, Mesoblast, Nanosonics, Patrys, Prescient and Universal Biosensors shed two percent or more; Alcidion, CSL, Immutep and Proteomics were down more than one percent; with Clinuvel and Opthea down by less than one percent.

## GENETIC TECHNOLOGIES

Genetic Technologies says customer receipts for the six months to December 30, 2021, was \$2,659,000 compared to \$15,000 for the six months to December 31, 2020.

Genetic Technologies told Biotech Daily that revenue came “sales of genetic tests, mainly through the Easy DNA direct-to-consumer brand and Genetype tests”.

The company said it a cash burn of \$2,157,000 for the three months to December 31, with cash and equivalents of \$13,509,000 at December 31, 2021.

Genetic Technologies was up 0.1 cents or 25 percent to 0.5 cents with 26.4 million shares traded.

## ALLEGRA ORTHOPAEDICS

Allegra says unaudited revenue for the six months to December 30, 2021, is expected to be \$3.2 million to \$3.5 million, with net loss between \$700,000 and \$1,000,000.

The company said the decrease in expected revenue and profit was primarily due to the Covid-19 pandemic and the “suspension or reduction of non-urgent elective surgeries”.

Allegra fell two cents or 12.5 percent to 14 cents.

## ADHERIUM

Adherium says it has received \$1,627,666 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Adherium said the rebate related to research and development expenditure for the year to June 30, 2021.

Adherium was up 0.1 cents or 7.7 percent to 1.4 cents with 1.5 million shares traded.

## CYNATA THERAPEUTICS

Cynata says it has received \$832,677 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Cynata said the rebate related to research and development expenditure for the year to June 30, 2021.

Cynata fell three cents or 5.45 percent to 52 cents.

## MEMPHASYS

Memphasys says director Andrew Goodall has sold a \$1.35 million convertible note to major shareholder, the Cottlesloe, Western Australia-based Peters Investments.

Memphasys said that should the note be converted under the current capital structure, Peters Investments would own about 32 percent of the company.

In 2019, Peters said it held 205,000,000 shares (27.93%) (BD: Nov 20, 2019).

Today, the company said that Mr Goodall had sold the note “to fund the purchase of a rural property” in New South Wales and the terms were unchanged.

Last year, Memphasys said that Peters Investments had invested \$1.65 million and Mr Goodall \$1.35 million through convertible notes, at 8.0 percent per annum and a 3.0 percent “facilitation fee”, converting at the lower of 6.0 cents a share or a 20 percent discount to any capital raising prior of more than \$1,000,000 prior to the repayment date of December 31, 2022, and with one unlisted option for every dollar, exercisable at six cents each by December 31, 2023 (BD: May 26, 2021).

Memphasys fell half a cent or six percent to 7.8 cents.

## CARDIEX

Cardiex says it is applying for a US Over-The-Counter Quality Exchange (OTCQX) market listing, and shareholders will vote on a 10-to-one consolidation.

Cardiex said that the consolidation would “ensure that the company’s share price is suitable for admission to quotation on [the] OTCQX – which has a 25 US cents minimum share price”.

The company said shareholders would be asked to vote on the consolidation at an extraordinary general meeting on February 16, 2022.

Cardiex was up 0.4 cents or 7.7 percent to 5.6 cents with 1.6 million shares traded.

## BIONOMICS

The Chicago-based William Blair & Co says it has become a substantial shareholder in Bionomics with 287,960,738 shares or 21.99 percent of the company.

William Blair & Co said the relevant interest was in relation to the public offer in the US giving it a relevant interest “notwithstanding that William Blair & Co has no right to acquire these shares or to control the voting rights attached to these shares”.

In December, Bionomics said it raised \$US20 million (\$A28 million) in an initial public offering of 1,622,000 American depositary shares on the Nasdaq (BD: Jan 16, 2022).

Today, William Blair & Co said the registered holders were Bionomics chair Dr Errol De Souza, Bionomics head of clinical development Liz Doolin, HSBC Custody nominees (Australia) Limited, BNP Paribas Nominees Pty Ltd and the Bank of New York Mellon.

Bionomics was up half a cent or 4.55 percent to 11.5 cents with 1.1 million shares traded.

## PACIFIC EDGE

Pacific Edge says Dr Peter Meintjes started work as chief executive officer on January 17, 2022, replacing former executive director David Darling.

In October, Pacific Edge said it had appointed Dr Meintjes as its new chief executive officer (BD: Oct 29, 2021).

Today, it said that Dr Meintjes and his family had relocated from Boston to Dunedin, New Zealand, where he would be based.

Pacific Edge fell one cent or 0.85 percent to \$1.165.